JP3724740B2 - Tube enteral nutrition containing coenzyme Q10 - Google Patents

Description

【００３２】
試験例１
慢性呼吸器疾患に対する本発明の経管経腸栄養剤の効果を下記の比較試験により評価した。
６名の慢性閉塞性肺疾患の患者（被験者）について、実施例３の濃厚流動食を濃厚流動食をＡ〜Ｃの３名に、また比較例１の濃厚流動食をＤ〜Ｆの３名に投与した。流動食は１日２回、朝食と昼食の間および昼食と夕食の間に、２００mLずつ（１回にＣｏＱ₁₀ １０mg）合計１日４００mLを４週間投与した。投与開始時、投与開始後２週間、４週間において、呼吸の状態、身体の調子および食欲について問診すると共に、上腕筋位（ＡＭＣ）、上腕三頭筋皮下脂肪（ＴＳＦ）、最大呼気圧（ＭＥＰ）、最大吸気圧（ＭＩＰ）および血中酸素飽和度（ＳａＯ２）を測定した。なお、ＡＭＣ、ＴＳＦ、ＭＥＰ、ＭＩＰおよびＳａＯ２は基準値に対する百分率にて表す。
【００３３】
その結果、ＣｏＱ₁₀を含有する実施例３の濃厚流動食を投与した場合には、極めて短期間の投与で呼吸筋力を示すＭＥＰおよびＭＩＰ、並びに換気機能を示すＳａＯ２について顕著な改善が認められ、さらに筋力の指標であるＡＭＣが向上した（表２を参照）。これに対し、ＣｏＱ₁₀を含まない比較例１の場合、身体の調子および食欲については改善が認められるが、呼吸筋力および換気機能等の呼吸機能はほとんど変化は観察されなかった（表３を参照）。
【００３４】
【表２】

【００３５】
試験例２
本発明の経管経腸栄養剤を術前・術後の患者に投与した場合の本発明の効果を、下記の比較試験により評価した。
消化器外科の高齢者待機手術１２例について、ＣｏＱ₁₀摂取群（ｎ＝６）；ライフロンＱＬ（ＣｏＱ₁₀ ５mg／１００mL含有、脂肪４５％、糖質３７％、タンパク質１８％；日清キョーリン製薬）投与、および対照群（ｎ＝６）；ライフロンＰＺ−II（脂肪２７.５％、糖質５２.５％、タンパク質２０％；日清キョーリン製薬）投与の２群にわけ、１日２回（２００kcal／２００mL／回）術前１週間、術後３〜１４日連日投与した。
その結果、術前呼吸筋力改善率がＣｏＱ₁₀摂取群では５／６例（８３.３％）と、対照群の１／６例（１６.７％）に比べて有意に高率であることが認められ、ならびに術後合併症発生率についてはＣｏＱ₁₀摂取群では１／６例（１６.７％）と、対照群の２／６例（３３.３％）に比べて低率で、ＣｏＱ₁₀摂取群には呼吸器合併症は認められなかった。さらに、人工呼吸器管理期間は、ＣｏＱ₁₀摂取群では平均１０.３時間と、対照群の１５.３時間に比して有意な短縮が認められ、ＣｏＱ₁₀含有経管経腸栄養剤を摂取することにより、患者を早期回復させ得ることが示された。ちなみに総医療費（手術費用を除く）に関してはＣｏＱ₁₀摂取群で明らかに安価であることが示された。
【００３６】
【発明の効果】
本発明によれば、慢性呼吸器疾患に伴う呼吸機能障害および栄養障害を極めて短期間に改善することができ、また術前・術後の患者への投与により患者の早期回復を促すことができる経管経腸栄養剤が提供される。本発明の経管経腸栄養剤は、ＣｏＱ₁₀の吸収性に優れ、且つ凝集反応などを起こさず、性状安定性がよく、風味も良好である。このため、慢性呼吸器疾患、特に慢性閉塞性肺疾患に起因する栄養障害の患者に栄養補給法により必要な栄養とエネルギーおよび十分な量のＣｏＱ₁₀を補給して、極めて短期間に患者の栄養状態を改善することができるばかりでなく、予後の改善および呼吸機能障害の修復等に極めて効果的である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a tube enteral nutrient for preventing and / or treating chronic respiratory diseases, or for promoting early recovery by administration to patients before and after surgery. Specifically, for prevention and / or treatment of chronic obstructive pulmonary disease containing coenzyme Q ₁₀ (hereinafter referred to as CoQ ₁₀ ), or for preoperative / postoperative administration to promote early recovery The present invention relates to a tube enteral nutrient useful for nutrition therapy.
[0002]
[Prior art]
CoQ ₁₀ has a general name ubidecalenone (molecular formula C ₅₉ H ₉₀ O ₄ , molecular weight 863.36) and hardly dissolves in water, but exhibits high solubility in ethers, etc., and decomposes by light to decompose hydroquinone, ubichromenol, etc. It is known as a substance that produces. CoQ ₁₀ is known as a vitamin-like substance having not only a biological activity as a coenzyme but also an effect of improving oxygen utilization efficiency. In addition to acting on congested tissues, CoQ ₁₀ is thought to have biological membrane stabilization and antioxidant effects, clinically improving the symptoms of angina, heart failure, ischemic heart disease, and muscular dystrophy. Pharmacological effects have been observed.
[0003]
However, CoQ ₁₀ is a lipophilic solid having a low melting point, and is poorly soluble in water and is known to have low absorbability in oral administration. Therefore, when administering CoQ _10, aims to improve the absorption properties, and separation, agglomeration, it is required to prevent causing crystallization, and others. It is also important to consider safety in order to ingest orally as a liquid food.
[0004]
On the other hand, chronic obstructive pulmonary disease (COPD) is an obstructive ventilation disorder caused by chronic bronchitis or pulmonary emphysema, and its respiratory function gradually declines after repeated acute exacerbations. However, this significantly impairs quality of life (QOL). In particular, it is expected to increase steadily with the aging of society.
[0005]
In addition, it is known that chronic respiratory diseases are accompanied by nutritional disorders due to deterioration of nutritional status simultaneously with a decrease in respiratory function. In recent years, in nutritional disorders associated with chronic respiratory diseases, especially chronic obstructive pulmonary diseases, the prognosis of the disease, respiratory muscle strength, obstructive ventilation disorder, exercise ability, infection defense ability, quality of life (QOL), etc. (Journal of Nutrition, Vol.99, No.6, pp.767-771, November 2001; JJPEN, Vol.23, No.5, pp.257-261, 2001). For this reason, nutritional therapy that manages the nutritional status of patients with chronic respiratory diseases accompanied by nutritional disorders and replenishes necessary nutrients is expected to prevent and improve poor prognosis and respiratory muscle disorders. However, to date, there has been no report of the relationship between nutritional disorders in chronic respiratory failure and CoQ ₁₀ and the use of CoQ ₁₀ for nutritional therapy, and the effect of CoQ ₁₀ in nutritional therapy for chronic obstructive pulmonary disease is unknown. It was.
[0006]
[Problems to be solved by the invention]
The object of the present invention is useful for the prevention and / or treatment of chronic respiratory diseases, particularly chronic obstructive pulmonary disease, or nutritional therapy for administering to a patient before or after surgery to promote early recovery, and The object is to provide a tube enteral nutrient that is excellent in absorbability of CoQ ₁₀ , has good property stability, and can effectively replenish CoQ ₁₀ . In particular, it is to provide an enteral enteral nutrient that can improve a patient's nutritional status and respiratory problems with short-term administration.
[0007]
[Means for Solving the Problems]
As a result of diligent studies to solve the above problems, the present inventors have added and blended insoluble CoQ ₁₀ that is sparingly water-soluble into a nutrient, and is excellent in dispersibility in liquid food and normal stability. In addition, the present inventors have found that a tube enteral nutrient excellent in CoQ ₁₀ absorbability can be obtained. In addition, when the tube enteral nutrient is administered or ingested to patients with chronic respiratory diseases such as chronic obstructive pulmonary disease, the nutritional state is improved in a short period of time, and the prognosis is prevented and improved. It has been found that respiratory dysfunction can be repaired. In addition, tube enteral nutrients and foods containing them may be administered or ingested not only by chronic obstructive pulmonary disease, but also by pre- and post-operative patients. It was possible to recover early, and as a result, it was possible to shorten the postoperative period of treatment, such as hospitalization days.
[0008]
Accordingly, the present invention relates to a tube enteral nutrient containing CoQ ₁₀ for preventing and / or treating chronic obstructive pulmonary disease, or administering it to a patient before or after surgery to promote early recovery. Specifically, the present invention relates to an enteral enteral nutrient comprising CoQ ₁₀ 0.0005 to 0.2 part by mass, protein 30 to 100 parts by mass, carbohydrate 50 to 400 parts by mass, and lipid 1 to 50 parts by mass. The content of CoQ _{10 in} the nutrient varies depending on the dosage form, desired administration and intake, etc., but when the enteral nutrient is liquid, 0.5 to 50 mg per 100 mL, preferably 1 It is in the range of -10 mg.
[0009]
The tube enteral nutrient of the present invention is used as a liquid food, preferably a high nutrition / high energy concentrated liquid food. In this case, the liquid food may be prepared in a liquid state by adding an aqueous fluid medium such as water, but it is prepared in a powder or paste form and used by dissolving or dispersing in a predetermined amount of the aqueous fluid medium at the time of ingestion. May be. Therefore, the liquid food of the present invention comprises CoQ ₁₀ 0.0005 to 0.2 parts by mass, protein 30 to 100 parts by mass, carbohydrates 50 to 400 parts by mass, lipid 1 to 50 parts by mass, and aqueous fluid medium 400 to 1000 parts by mass. The energy per 100 mL is 50 kcal or more.
[0010]
The tube enteral nutrition of the present invention further includes various vitamins, minerals, dietary fiber, other nutrients such as polyunsaturated fatty acids, stabilizers such as dispersants and emulsifiers, sweeteners, flavoring ingredients, flavors, etc. Can be blended. The tube enteral nutrient of the present invention reliably supplies the necessary nutrition and energy containing CoQ ₁₀ to patients with chronic respiratory diseases accompanied by nutritional disorders, particularly chronic obstructive pulmonary disease, by the enteral nutrition supplementation method. It can be administered to patients before and after surgery to promote early recovery.
[0011]
The present invention also relates to a food, preferably a liquid food containing the tube enteral nutrient. The liquid food may be prepared from the beginning as a liquid food, but may be prepared in a powder or paste form and dissolved in a predetermined amount of an aqueous fluid medium. In order to improve the flavor of the liquid food, it is preferable to add various additives such as a taste ingredient, flavor and the like. The food of the present invention is useful for home treatment, QOL or improvement of prognosis of patients with relatively mild symptoms.
[0012]
DETAILED DESCRIPTION OF THE INVENTION
Since CoQ ₁₀ is poorly soluble in water, it is usually dissolved in non-hydrophilic organic solvents such as vegetable oils and animal oils, or dispersed in an aqueous solution using an emulsifier, a dispersant or a surfactant.・ Used after emulsification. However, the tube enteral nutrient of the present invention only needs to be blended together with other nutrients, specifically proteins, carbohydrates, lipids, etc. CoQ ₁₀ in the nutrient is excellent in dispersibility, Does not easily aggregate or settle. The tube enteral nutrient of the present invention contains 0.0005 to 0.2 parts by mass of CoQ ₁₀ , preferably 0.001 to 0.05 parts by mass. As described above, in the case of a liquid food, the content of CoQ ₁₀ per 100 mL is in the range of 0.5 to 50 mg, preferably 1 to 10 mg. This is the daily dose of CoQ ₁₀ and also the dispersion stability. It is determined appropriately in consideration of the taste and flavor. The daily dose of CoQ ₁₀ varies depending on the health condition of the intake person, but is usually in the range of 5 to 200 mg, preferably 10 to 100 mg.
[0013]
When the use of the tube enteral nutrient of the present invention is a liquid food, the composition and amount of each component such as protein, carbohydrate, lipid and plant fiber is determined by the energy amount of the liquid food itself, each desired nutrient amount, although the amounts and the like of CoQ ₁₀ to be blended may be appropriately determined in consideration of the energy per liquid diet 100mL is above 50 kcal, preferably the formulation of each component so that the above to 230kcal less 100kcal adjust.
[0014]
Examples of the protein that can be used in the tube enteral nutrient of the present invention include casein salts such as casein, sodium caseinate or casein calcium, animal proteins such as egg protein, milk protein, meat protein; soy protein or soy peptide, etc. Plant proteins are included, and only one or a combination of two or more of these proteins may be used. Moreover, degradation products and amino acids of these proteins can be used. The protein content is 30 to 100 parts by mass, preferably 40 to 60 parts by mass. Specifically, the protein content is 5 to 30%, preferably 10 to 25% of the total amount of liquid food.
[0015]
Examples of carbohydrates that can be used in the tube enteral nutrient of the present invention include maltodextrin, dextrin, powder cake, monosaccharides such as glucose and fructose, disaccharides such as maltose and lactose, granulated sugar, and oligosaccharide. It is included, and only one type or a combination of two or more of these carbohydrates may be used. The content of the saccharide is 50 to 400 parts by mass, preferably 100 to 200 parts by mass, specifically 10 to 70%, preferably 50 to 70% of the total energy amount of the liquid food.
[0016]
Examples of lipids that can be used include rice bran oil, soybean oil, cottonseed oil, safflower oil, sunflower oil, corn oil, rapeseed oil, olive oil, palm oil, perilla oil, sesame oil, coconut oil and other vegetable oils; Fish oil; medium chain fatty acid triglycerides (MCT); and other synthetic triglycerides and the like, and only one or a combination of two or more of these lipids may be used. The lipid content is 1 to 50 parts by mass, preferably 15 to 35 parts by mass, specifically, 1 to 50%, preferably 15 to 45% of the total energy of the liquid food.
[0017]
Examples of dietary fibers that can be used include indigestible polysaccharides such as cellulose, lignin, resistant starch, polydextrose, oligosaccharides, and guar gum enzymatic degradation products. Of these dietary fibers, only one or a combination of two or more may be used. The content of dietary fiber is 0 to 50 parts by mass, preferably 0.5 to 45 parts by mass.
[0018]
Examples of vitamins that can be added include vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin D, vitamin K, niacin, folic acid, pantothenic acid, etc. These vitamins may be included, and these vitamins may be used alone or in combination of two or more. The amount of each vitamin should be determined according to the intake (target intake) described in the 80-year-old male lifestyle activity intensity I described in the 6th revised Japanese nutritional requirements (published by 1st publisher), for example. Can do.
[0019]
Examples of minerals that can be added include calcium, iron, sodium, potassium, phosphorus, magnesium, and the like, and only one or a combination of two or more of these minerals may be used. The blending amount of these minerals can be determined in accordance with the intake amount (target intake amount) described in the sixth revised “Japanese nutritional requirement” in the same manner as described above.
[0020]
However, deficiency of magnesium can also induce neurological diseases, mental illnesses, arrhythmia, etc., and calcium can prevent or improve osteoporosis, so it is preferable to add and mix these mineral components in the enteral enteral nutrient . The blending amount is usually in the range of about 500 to 1000 mg / L for calcium and in the range of about 250 to 500 mg / L for magnesium. At that time, in order to prevent diseases such as myocardial infarction and ischemic heart disease, it is preferable to mix calcium and magnesium so that the weight ratio of Ca: Mg = 2: 1 to 1: 1.
[0021]
The reason for the above appropriate mixing ratio is that magnesium has the function of activating the enzyme ATPase which is an energy source in the cell, and the ATPase activates the calcium pump present in the cell, thereby This is because the calcium concentration is kept low. Therefore, by adding an appropriate amount of magnesium, the intracellular calcium concentration is also kept low by magnesium in vascular smooth muscle. As a result, the occurrence of vascular smooth muscle spasm is prevented and ischemic heart disease is prevented. The
[0022]
Examples of polyunsaturated fatty acids that can be added include linoleic acid, α-linolenic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), of which only one or a combination of two or more It may be used.
[0023]
Examples of emulsifiers that can be added to the enteral nutrient of the present invention as additives include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, phospholipid, gum arabic, xanthan gum, Tragacanth gum, guar gum, locust bean gum or a mixture of two or more of these are included. Further, for example, flavoring ingredients such as sodium chloride, sodium glutamate, citric acid, sodium citrate, fruit juice, and flavors such as coffee flavor, matcha flavor, and milk flavor can be appropriately blended.
[0024]
The tube enteral nutrient of the present invention is provided in the form of a liquid food dissolved or dispersed in an aqueous fluid medium such as water or warm water, but without adding the aqueous fluid medium, it is a powder, solid, paste It can be in a form such as a shape. In this case, these are used by dissolving or dispersing in an aqueous fluid medium such as water or warm water in advance or at the time of ingestion. The liquid food can be prepared according to a conventional method. For example, a liquid food can be produced by putting each weighed component into water, thoroughly mixing, emulsifying, filling and sealing in a retort pouch, and sterilizing.
[0025]
The liquid food obtained in this way can supply a sufficient amount of CoQ ₁₀ to patients with chronic respiratory diseases with nutritional disorders and at the same time provide the necessary nutrition and energy. Can be administered to other patients to promote early recovery.
[0026]
The present invention will be described with reference to the following examples, but the present invention is not limited to the following examples. In all the examples of the present invention, CoQ ₁₀ manufactured by Nisshin Pharma Co., Ltd. was used.
[0027]
【Example】
Example 1
Each component was weighed according to the formulation shown in Table 1. Next, casein sodium, casein calcium, maltodextrin, mineral dispersion, polyglycerin fatty acid ester, oligosaccharide, rice bran oil, rapeseed oil and MCT (previously CoQ ₁₀ , fat-soluble vitamin and water-soluble vitamin in pure water at about 65 ° C. Was dispersed) and mixed.
After mixing each component, the mixed solution was put into a homomixer and roughly emulsified at about 9000 rpm for 15 minutes. Next, the mixed solution was heated to 65 ° C. and allowed to stand for 10 minutes, and then finely emulsified with a high-pressure emulsifier (500 kf / cm ² 2 passes). The obtained emulsion was cooled to about 20 ° C., and a fragrance was added, followed by a mess up. The filling tank was cooled to about 8 ° C., and the obtained emulsion was added while stirring at 200 rpm. Next, after filling the pouch with 225 g of this liquid from the filling tank, the pouch was sealed with nitrogen substitution, and sterilized at 121 ° C. for 14 minutes to obtain a concentrated liquid food.
The resulting concentrated liquid food has an energy of 100 kcal per 100 mL. As a result of analyzing this concentrated liquid food, the content of CoQ ₁₀ was 5 mg / 100 mL, the average particle size was 0.87 μm, the pH was 6.9, and the osmotic pressure was 426 m 0 sm. The property was a milky white emulsion with a slightly sweet flavor. This concentrated liquid food was good in the content of CoQ ₁₀ and its emulsion stability and flavor.
[0028]
Example 2
Each component was weighed according to the formulation shown in Table 1. Next, CoQ ₁₀ , fat-soluble vitamins and water-soluble vitamins, proteins, carbohydrates, lipids, minerals and emulsifiers previously dispersed in MCT were added to and mixed with pure water at about 65 ° C. The mixed solution was put into a homomixer and roughly emulsified at about 9000 rpm for 20 minutes. Subsequently, fine emulsification (500 kgf / cm ² 2 passes) was performed with a high-pressure emulsifier. The obtained emulsion was cooled to about 20 ° C., and a fragrance was added, followed by a mess up. The liquid that had been made up was transferred to a filling tank, and after filling with 226 g in the pouch, the pouch was sealed while performing nitrogen replacement, and sterilized at 123 ° C. for 14 minutes to obtain a concentrated liquid food.
The resulting concentrated liquid food has an energy of 150 kcal per 100 mL. As a result of analyzing this concentrated liquid food, the content of CoQ ₁₀ was 7.5 mg / 100 mL, pH 6.88, average particle size 0.96 μm, and osmotic pressure 456 m0sm. The property was a milky white emulsion with a slightly sweet flavor. This concentrated liquid food was good in the content of CoQ ₁₀ and its emulsification stability and flavor as in Example 1.
[0029]
Example 3
Along with the amounts of protein, carbohydrate, lipid, mineral and emulsifier shown in Table 1, the amount of dietary fiber (guagum enzyme degradation product) shown in the same table was added, and a concentrated liquid food was obtained in the same manner as in Example 2. The resulting concentrated liquid food has an energy of 100 kcal per 100 mL. Further, the content of CoQ ₁₀ in this concentrated liquid food was 5 mg / 100 mL, pH 7.01, average particle size 0.69 μm, and osmotic pressure 432 m0sm. The property was a milky white emulsion with a slightly sweet flavor. This concentrated liquid food was good in the content of CoQ ₁₀ and its emulsification stability and flavor as in Example 1.
[0030]
Comparative Example 1
A concentrated liquid food was obtained in the same manner as in Example 3 except that CoQ ₁₀ was not added. The resulting concentrated liquid food has an energy of 100 kcal per 100 mL. Further, the content of CoQ ₁₀ in this concentrated liquid food was 5 mg / 100 mL, pH 7.01, average particle size 0.68 μm, and osmotic pressure 430 m0sm. The property was a milky white emulsion with a slightly sweet flavor. This concentrated liquid food was good in emulsification stability, flavor and the like as in Example 3.
[0031]
[Table 1]

[0032]
Test example 1
The effect of the tube enteral nutrient of the present invention on chronic respiratory diseases was evaluated by the following comparative test.
For 6 patients (subjects) with chronic obstructive pulmonary disease, the concentrated liquid food of Example 3 was changed to the concentrated liquid foods A to C, and the concentrated liquid food of Comparative Example 1 was changed to 3 persons D to F. Administered. The liquid food was administered twice a day, 200 mL each (between breakfast and lunch, and between lunch and dinner) (CoQ ₁₀ 10 mg at a time) for a total of 400 mL per day for 4 weeks. At the start of administration, 2 weeks and 4 weeks after the start of administration, the patient was asked about respiratory status, physical condition and appetite, as well as brachial muscle position (AMC), triceps subcutaneous fat (TSF), and maximum expiratory pressure (MEP) ), Maximum inspiratory pressure (MIP) and blood oxygen saturation (SaO2). AMC, TSF, MEP, MIP and SaO2 are expressed as percentages relative to the reference value.
[0033]
As a result, when the concentrated liquid food of Example 3 containing CoQ ₁₀ was administered, MEP and MIP showing respiratory muscle strength and SaO2 showing ventilation function were recognized in a very short time administration, and a marked improvement was observed. Furthermore, AMC, which is an index of muscle strength, was improved (see Table 2). On the other hand, in the case of Comparative Example 1 containing no CoQ ₁₀ , although improvement was observed in the physical condition and appetite, changes in respiratory function such as respiratory muscle strength and ventilation function were hardly observed (see Table 3). ).
[0034]
[Table 2]

[0035]
Test example 2
The effects of the present invention when the tube enteral nutrient of the present invention was administered to patients before and after surgery were evaluated by the following comparative test.
For 12 elderly patients undergoing gastroenterological surgery, CoQ ₁₀ intake group (n = 6); Ritron QL (CoQ ₁₀ containing 5 mg / 100 mL, fat 45%, carbohydrate 37%, protein 18%; Nissin Kyorin Pharmaceutical) ) Administration, and control group (n = 6); divided into two groups: lifelon PZ-II (fat 27.5%, carbohydrate 52.5%, protein 20%; Nissin Kyorin Pharmaceutical) The dose was administered once (200 kcal / 200 mL / time) for 1 week before the operation and every day for 3 to 14 days after the operation.
As a result, the preoperative respiratory muscle strength improvement rate was significantly higher in 5/6 cases (83.3%) in the CoQ ₁₀ intake group than in 1/6 cases (16.7%) in the control group. In addition, the incidence of postoperative complications was lower in 1/6 cases (16.7%) in the CoQ ₁₀ intake group than in 2/6 cases (33.3%) in the control group, There were no respiratory complications in the CoQ ₁₀ intake group. Furthermore, ventilator management period, the average 10.3 hours in CoQ ₁₀ intake group, significant shortening was observed compared to 15.3 hours in the control group, ingestion of CoQ ₁₀ containing transluminal enteral nutrient It has been shown that the patient can be recovered early. Incidentally, it was shown that the total medical costs (excluding surgical costs) were clearly cheaper in the CoQ ₁₀ intake group.
[0036]
【The invention's effect】
According to the present invention, respiratory dysfunction and nutritional disorders associated with chronic respiratory diseases can be improved in a very short time, and early recovery of patients can be promoted by administration to patients before and after surgery. A tube enteral nutrient is provided. The tube enteral nutrient of the present invention has excellent CoQ ₁₀ absorbability, does not cause an agglutination reaction, and has good property stability and good flavor. For this reason, patients with nutritional disorders caused by chronic respiratory disease, particularly chronic obstructive pulmonary disease, are supplemented with the necessary nutrition and energy and a sufficient amount of CoQ ₁₀ by nutritional supplementation, and the patient's nutrition In addition to being able to improve the condition, it is extremely effective in improving prognosis and repairing respiratory dysfunction.

Claims (2)

Coenzyme Q ₁₀ 0.0005 to 0.2 parts by weight, 30 to 100 parts by weight protein, 50 to 400 parts by weight carbohydrate, 1 to 50 parts by weight lipid and 400 to 1000 parts by weight aqueous fluid medium, and per 100 mL A tube enteral nutrient for the prevention and / or treatment of chronic obstructive pulmonary disease, characterized by having an energy of 50 kcal or more. Coenzyme Q ₁₀ 0.0005 to 0.2 parts by weight, 30 to 100 parts by weight protein, 50 to 400 parts by weight carbohydrate, 1 to 50 parts by weight lipid and 400 to 1000 parts by weight aqueous fluid medium, and per 100 mL A tube enteral nutrient for administration to pre- and post-operative patients to promote early recovery, characterized by energy of 50 kcal or more.